Case Report
Accepted on 09 Jan 2026
Targeted interleukin-6 (IL-6) blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers
in Inflammation
- 159 views
Case Report
Accepted on 09 Jan 2026
in Inflammation
Review
Published on 09 Jan 2026
in Inflammation
Original Research
Published on 09 Jan 2026
in Inflammation
Review
Published on 09 Jan 2026
in Inflammation
Original Research
Published on 08 Jan 2026
in Inflammation
Original Research
Published on 08 Jan 2026
in Inflammation
Review
Accepted on 07 Jan 2026
in Inflammation
Original Research
Published on 07 Jan 2026
in Inflammation
Original Research
Published on 07 Jan 2026
in Inflammation
Original Research
Published on 07 Jan 2026
in Inflammation
Original Research
Published on 07 Jan 2026
in Inflammation
Mini Review
Published on 07 Jan 2026
in Inflammation
Review
Published on 07 Jan 2026
in Inflammation
Original Research
Published on 07 Jan 2026
in Inflammation
Case Report
Published on 06 Jan 2026
in Inflammation
Original Research
Published on 06 Jan 2026
in Inflammation
Original Research
Published on 06 Jan 2026
in Inflammation
Original Research
Published on 06 Jan 2026
in Inflammation
Original Research
Published on 06 Jan 2026
in Inflammation
Review
Published on 05 Jan 2026
in Inflammation
Review
Published on 05 Jan 2026
in Inflammation
Original Research
Published on 05 Jan 2026
in Inflammation
Original Research
Published on 05 Jan 2026
in Inflammation
Original Research
Published on 05 Jan 2026
in Inflammation